Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Nov 8, 2011 · 10-Q · 39 days after period end · 0001193125-11-302232
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $22.94M | $3.40M |
| Net Income | $5.17M | -$12.41M |
| EPS Diluted | $0.05 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Sep 30, 2011 · filed Nov 8, 2011 · 39 d after period end
